Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.

Nathan, Steven D; Fernandes, Peter; Psotka, Mitchell; Vitulo, Patrizio; Piccari, Lucilla; Antoniou, Katerina; Nikkho, Sylvia M; Stockbridge, Norman

Nathan, Steven D; Fernandes, Peter; Psotka, Mitchell; Vitulo, Patrizio; Piccari, Lucilla; Antoniou, Katerina; Nikkho, Sylvia M; Stockbridge, Norman.

Afiliação

Nathan SD; Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute Falls Church Virginia USA.
Fernandes P; Bellerophon Therapeutics Inc., Regulatory, Safety and Quality Department Warren New Jersey USA.
Psotka M; Division of Cardiology and Nephrology, Food and Drug Administration Silver Spring Maryland USA.
Vitulo P; Department of Pulmonary Medicine, IRCCS Mediterranean Institute for Transplantation and Advanced Specialized, Therapies Palermo Sicilia Italy.
Piccari L; Hospital del Mar, Pulmonary Hypertension Unit, Department of Pulmonary Medicine Barcelona Catalunya, ES Spain.
Antoniou K; University of Crete School of Medicine, Department of Thoracic Medicine Heraklion Crete Greece.
Nikkho SM; Global Clinical Development, Bayer AG Berlin Germany.
Stockbridge N; US Food and Drug Administration, Division of Cardiology and Nephrology Silver Spring Maryland USA.

Pulm Circ ; 12(4): e12178, 2022 Oct.

Article em En | MEDLINE | ID: mdl-36578976

Palavras-chave

clinical trial design; interstitial lung disease; pulmonary hypertension

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Pulm Circ Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Pulm Circ Ano de publicação: 2022 Tipo de documento: Article